Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/TRAIL-Cisplatin combination therapy in cervical cancer

1. Narayan, G.
2. Xie, D.
3. Ishdorj, G.
4. Scotto, L.
5. Mansukhani, M.
6. Pothuri, B.
7. Wright, J.D.
8. Kaufmann, A.M.
9. Schneider, A.
10. Arias-Pulido, H.
11. Murty, V.V.